

## Promore Pharma participates in “Småbolagsdagarna 2021”, an event organized by Aktiespararna

**STOCKHOLM, 26 May, 2021 -- CEO Jonas Ekblom presents Promore Pharma AB at a digital event for small- and mid-sized companies, organized by Aktiespararna, on 9 June at 13.30.**

Jonas Ekblom, CEO of Promore Pharma, presents the company's revised strategy with a focus on skin scar prevention and pharmaceutical product development, as well as the new share issue that the company plans to carry out on 3-17 June, 2021. The presentation will be held in Swedish.

Participants have the opportunity to ask questions in connection with the presentation by sending text messages to +46 79 347 98 45 or by emailing [event@aktiespararna.se](mailto:event@aktiespararna.se). The questions will be conveyed by Aktiespararna's moderator in connection with the general discussion after the presentation. Questions can be submitted now, or in connection with the presentation.

The presentation can be followed live at [aktiespararna.se/tv/live](http://aktiespararna.se/tv/live). The event is open to everyone and does not require membership in Aktiespararna. No registration is required to follow the event digitally.

The following day, all presentations will be posted on [aktiespararna.se/tv/evenemang](http://aktiespararna.se/tv/evenemang).

### For additional information, please contact

---

Jonas Ekblom, CEO  
Phone: [+46] 736 777 540  
E-mail: [jonas.ekblom@promorepharma.com](mailto:jonas.ekblom@promorepharma.com)

Erik Magnusson, CFO  
Phone: [+46] 708 565 245  
E-mail: [erik.magnusson@promorepharma.com](mailto:erik.magnusson@promorepharma.com)

Promore Pharmas Certified Adviser is Erik Penser Bank  
Tel: [+46] 8-463 83 00  
E-mail: [certifiedadviser@penser.se](mailto:certifiedadviser@penser.se)

### Promore Pharma in brief

---

Promore Pharma is a biopharmaceutical company specialized in the development of therapeutic peptides. The company's aim is to develop first-in-category pharmaceuticals for indications with high unmet medical needs, where very few efficacious prescription pharmaceuticals are available. Promore Pharma's two projects are undergoing clinical development and have a very strong safety profile since the products are based on endogenous substances that are administered locally. The leading project, ensereptide (PXL01), that will be used for prevention of post-surgical scarring, is being prepared for a clinical phase II-trial if the peptide can prevent the formation of unesthetic scars on the skin. Ropocamptide (LL-37) has recently been evaluated in a clinical phase IIb study with positive results in patients with venous leg ulcers (VLUs). The product candidates can also be deployed for other indications, such as preventing unfavorable tissue attachments (adhesions) after different kinds of surgical procedures and treatment of diabetic foot ulcers. The company is listed on Nasdaq First North Growth Market.

Press Release  
26 May 2021



---

**Attachments**

---

[Promore Pharma participates in "Småbolagsdagarna 2021", an event organized by Aktiespararna](#)